Furthermore, the risk of reduced LVEF between patients treated with CHOP+/−R versus CEpOP+/−R was similar even after adjustments for age, sex, co-morbidities (hypertension, diabetes mellitus, and history of heart disease), smoking status, BMI, histology subtype, molecular subtype of DLBCL, and use of rituximab (Figure 4A). This evidence concerns the gene DDIT3 and diabetes mellitus.